Chris Lo

All articles by Chris Lo

1. Blocking generic competition: will naming and shaming work?

   With the US political spotlight still centred firmly on drug prices, President Donald Trump’s 11 May speech on the topic…
   Read More…

   11 Jul
2. Shaky foundations: the flaws in animal research reporting

   Animal studies represent one of the fundamental layers of modern clinical research. Preclinical testing of drug candidates on animal models…
   Read More…

   20 Jun
3. Can the gene and cell therapy revolution scale up?

   As innovative gene and cell therapies continue to make the transition from the laboratory to the clinic, they are bringing…
   Read More…

   28 May
4. CRISPR: a seismic shift in gene editing

   Given the ubiquity of CRISPR today, it’s hard to believe that the technology was little more than a blip on…
   Read More…

   23 May
5. Biotech M&A: will the 2018 surge last?

   Over the last 20 years, the pace of mergers and acquisitions (M&A) in the biotech and pharma industries seems to…
   Read More…

   14 May
6. Boosting biosimilar uptake in the US: what needs to change?

   While the debate over drug prices rages on in the US, there’s one benefit that is often trumpeted by the…
   Read More…

   2 May
7. US drug pricing: could the industry regulate itself?

   Back in September 2016, with the US presidential election in full swing and drug prices high on the public agenda,…
   Read More…

   5 Apr
8. Is a universal flu vaccine on the horizon?

   As the 2018 flu season – one of the most severe in recent years – finally shows signs of winding…
   Read More…

   13 Mar
9. Cracking the mysteries of Alzheimer’s disease

   Looking back over the last 15 years of Alzheimer’s disease (AD) research, it can seem that there’s scant room for…
   Read More…

   6 Mar
10. Cost control: drug pricing policies around the world

    What value do we ascribe to innovative medicines, and how much are we willing to pay for them? The answers…
    Read More…

    12 Feb